



## **Crescendo Biologics is category winner for Biopharma and Vaccines in 2023 UK DIT Life Sciences Innovator Showcase**

**Cambridge, UK, 31 January 2023** – Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces that it has been named as the 2023 category winner for Biopharma and Vaccines in the Life Sciences Innovator Showcase, sponsored by the UK Department for International Trade (DIT).

Following a rigorous procedure, selected companies have been chosen by DIT to represent UK excellence across the life sciences sector. The 2023 Showcase includes cutting edge companies across six categories: Biopharma & Vaccines; Application, Product & Service Design; Diagnostics & Precision Medicine; Digital Solutions; Medical Technologies; Medicines Development & Delivery.

The Showcase is sponsored by the UK's Department for International Trade, specialising in helping overseas companies set up and invest in the UK and assisting UK companies to succeed in global trade.

More information about the Innovator Showcase can be found at [www.lifesciencesinnovator.co.uk](http://www.lifesciencesinnovator.co.uk).

**Theodora Harold, Chief Executive Officer of Crescendo Biologics, said:** “Speaking on behalf of the whole of the Crescendo Biologics team, we are immensely proud to have been chosen as the category winner for Biopharma and Vaccines in the 2023 Life Sciences Innovator Showcase. The UK has a rich heritage in creating scientific breakthroughs for the benefit of patients, and I am very fortunate to lead an outstanding group of scientists and clinicians who work tirelessly each day to drive our portfolio of therapeutic candidates forward. This recognition by the UK Department for International Trade is further validation of the power and potential of our proprietary Humabody® platform, and the quality of the team at Crescendo.”

-Ends-

**For more information, please contact:**

### **Crescendo Biologics**

Michael Booth, CFO  
+ 44 (0)1223 497140  
[investors@crescendobiologics.com](mailto:investors@crescendobiologics.com)  
[media@crescendobiologics.com](mailto:media@crescendobiologics.com)

### **Instinctif Partners**

Melanie Toyne-Sewell  
Adam Loudon  
+ 44 (0)20 7457 2020  
[crescendo@instinctif.com](mailto:crescendo@instinctif.com)

### **About Crescendo Biologics**

Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics.



Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours ([NCT04839991](#)). CB693 is a half-life extended CD137 x MSLN Humabody and is the second proprietary clinical candidate from Crescendo's T cell enhancing pipeline. Crescendo is also developing CB213, a preclinical PD-1 x LAG-3 multi-specific Humabody.

The Company's ability to develop multi-functional Humabody therapeutics is based on its unique, patent protected, transgenic mouse platform generating fully human V<sub>H</sub> domain building blocks (Humabody V<sub>H</sub>). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel pharmacology and superior bio-distribution. This can lead to larger therapeutic windows compared to conventional IgG approaches. Humabody-based formats can also be applied across a range of non-cancer indications.

Beyond Crescendo's proprietary pipeline, the Company has global, multi-target discovery and development collaborations with both Takeda and BioNTech and an exclusive, worldwide licensing agreement with Zai Lab for ZL-1102 (formerly CB001, an anti-IL-17A targeting Humabody), which is expected to enter global Phase 2 clinical development in patients with psoriasis.

Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda and Quan Capital.

For more information, please visit [www.crescendobiologics.com](http://www.crescendobiologics.com) and follow [@HUMABODY](#).